83 related articles for article (PubMed ID: 24052619)
1. Re: selective inhibition of Her2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.
Kapoor S
J Natl Cancer Inst; 2013 Oct; 105(19):1515. PubMed ID: 24052619
[No Abstract] [Full Text] [Related]
2. Re: novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
Lopez-Lopez E; Gutierrez-Camino A; Martin-Guerrero I; Garcia-Orad A
J Natl Cancer Inst; 2013 Oct; 105(19):1512. PubMed ID: 24013179
[No Abstract] [Full Text] [Related]
3. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.
Shim JS; Rao R; Beebe K; Neckers L; Han I; Nahta R; Liu JO
J Natl Cancer Inst; 2012 Oct; 104(20):1576-90. PubMed ID: 23042933
[TBL] [Abstract][Full Text] [Related]
4. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
5. Oxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer Cells.
Soprano M; Sorriento D; Rusciano MR; Maione AS; Limite G; Forestieri P; D'Angelo D; D'Alessio M; Campiglia P; Formisano P; Iaccarino G; Bianco R; Illario M
PLoS One; 2016; 11(6):e0155970. PubMed ID: 27280849
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
De Mattos-Arruda L; Cortes J
Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
[TBL] [Abstract][Full Text] [Related]
7. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
Ellis MJ
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
[No Abstract] [Full Text] [Related]
8. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
9. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
10. Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.
Brüning A; Vogel M; Burger P; Rahmeh M; Gingelmaier A; Friese K; Lenhard M; Burges A
Biochem Biophys Res Commun; 2008 Dec; 377(4):1309-14. PubMed ID: 19000651
[TBL] [Abstract][Full Text] [Related]
11. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.
Chow WA; Guo S; Valdes-Albini F
Anticancer Drugs; 2006 Sep; 17(8):891-903. PubMed ID: 16940799
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.
Jhaveri K; Chandarlapaty S; Iyengar N; Morris PG; Corben AD; Patil S; Akram M; Towers R; Sakr RA; King TA; Norton L; Rosen N; Hudis C; Modi S
Clin Breast Cancer; 2016 Aug; 16(4):276-83. PubMed ID: 26726007
[TBL] [Abstract][Full Text] [Related]
13. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
14. Ribociclib in HR-positive, HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
[No Abstract] [Full Text] [Related]
15. C/EBPalpha reverses the anti-adipogenic effects of the HIV protease inhibitor nelfinavir.
Dowell P; Lane MD
Biochem Biophys Res Commun; 2005 Feb; 327(2):571-4. PubMed ID: 15629151
[TBL] [Abstract][Full Text] [Related]
16. [HER2 testing in breast cancer].
Yoshimura K
Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
[No Abstract] [Full Text] [Related]
17. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
Besse L; Besse A; Stolze SC; Sobh A; Zaal EA; van der Ham AJ; Ruiz M; Phuyal S; Büchler L; Sathianathan M; Florea BI; Borén J; Ståhlman M; Huber J; Bolomsky A; Ludwig H; Hannich JT; Loguinov A; Everts B; Berkers CR; Pilon M; Farhan H; Vulpe CD; Overkleeft HS; Driessen C
Cancer Res; 2021 Sep; 81(17):4581-4593. PubMed ID: 34158378
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Okubo K; Isono M; Asano T; Sato A
Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
[TBL] [Abstract][Full Text] [Related]
19. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
[TBL] [Abstract][Full Text] [Related]
20. Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.
Avan A; Avan A; Maftouh M; Ghayour Mobarhan M; Shahidsales S; Gholamin S
J Clin Oncol; 2015 May; 33(15):1711-2. PubMed ID: 25870088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
